{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:06:52Z","timestamp":1789553212973,"version":"build-2803163510"},"reference-count":0,"publisher":"ALUNA","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiadomo\u015bci Lekarskie"],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Objective: to compare effects and side-effect profiles between mirabegron\u2002monotherapy and 2 combination treatments including mirabegron in patients with OAB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>Methods: Study is nonrandomized, prospective, and observational; conducted in 22 centers, 400\u2002patients with OAB symptoms. Patients administered 50 mg monotherapy of\u2002mirabegron for 8 weeks. Responders received monotherapy (Group 0, n=109)\u2002and non-responders allocated to double therapy with mirabegron plus Solifenacin 5mg (Group 1, n=145) or mirabegron plus Flavoxate\/Uripas (Group 2, n=146) for an additional eight weeks. Providing bladder volume,\u2002postvoid residual and BWT served as primary end points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results: Prevalence of urgency, frequency, and nocturia was high in cohort (92.8%, 88.5%, and 76.5%), but that of UUI35 was low\u2002at 9%. This indicates that patients are clearly of OAB-dry phenotype. Mixed storage-voiding symptom\u2002was most frequent among 53.8%. An unusual baseline comparison population along to chew, - 200% male\u2002and severe symptom\u2019 GROUPS 2 BWT a benefit of mirabegron\\+\\-Solifenacin); one could get; other couldn\u2019t (-36ml vs. -31ml). End-point analysis did\u2002not allow exclusion of therapeutic equipoise of REGULAR vs. DROP for final PVR (between-group difference: -1.48 mL, p = 0.065).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Conclusions: Beta-3 agonist as monotherapy is\u2002a potent, multimodality first-line therapy with strong influence of severe disease. Each of combinatory treatments show characteristic effect on phenotype-specific increase in\u2002bladder capacity. Mirabegron flaoxate could be considered for detrusor hypertrophy and combination of mirabegron Solifenacin would\u2002stimulate voiding facilitate. These proof of concept data justify PPTP based on objective biomarkers such as BWT and PVR to select combination therapy in what is another small step in our journey towards precision\u2002medicine for OAB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36740\/wlek\/222508","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:39:33Z","timestamp":1789551573000},"page":"1572-1580","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Therapeutic Potential of Beta-3 Adrenergic Agonists in Overactive Bladder: A Comparative Analysis of Monotherapy versus Combination Therapy Strategies"],"prefix":"10.36740","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9564-6626","authenticated-orcid":false,"given":"Bushra A.","family":"Lafta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-1505","authenticated-orcid":false,"given":"Jawad K.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-8446","authenticated-orcid":false,"given":"Safaa A.","family":"Mohssin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-1075","authenticated-orcid":false,"given":"Firas S.","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-0663","authenticated-orcid":false,"given":"shaymaa Fadhil","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-3080","authenticated-orcid":false,"given":"Noor","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2026,7,30]]},"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"link":[{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/pdf-222508-145220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/pdf-222508-145220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:39:38Z","timestamp":1789551578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wiadomoscilekarskie.pl\/Exploring-the-Therapeutic-Potential-of-Beta-3-Adrenergic-Agonists-in-Overactive-Bladder,222508,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["222508"],"URL":"https:\/\/doi.org\/10.36740\/wlek\/222508","relation":{},"ISSN":["0043-5147","2719-342X"],"issn-type":[{"value":"0043-5147","type":"print"},{"value":"2719-342X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}